News and analysis of Biotech stocks. No buy or sell recommendations.

Visit SeekingAlpha Biotech Stocks

Myriad Genetics: I Told You So

Posted on July 01, 2008

On May 13, 2008, I wrote about the likelihood of Myriad Genetics (MYGN) Flurizan failing its phase III clinical studies for Alzheimer's disease. I don t want to revisit the rationale for my skepticism again, but those interested can view the article and comments that describe it in some detail. ...

Original article link


disease , phase